When we analyzed the levels of the two known TAM receptor ligands, GAS6 and PROS1, in circulating CD4+CD11b- T cells, we found a significant increase of GAS6 level as well as the % of CD4+ T cell expressing GAS6 (Fig 1N–1P), but not differences in PROS1 expression in patients with HIMS compared with MS or HC (Fig 1Q–1S). Here, GAS6 is linked to myeloid sarcoma.